Beginner's Mind

Beginner's Mind

Download on the App Store

All Beginner's Mind episodes

  • #11: Digital Health

    Digital health is a technology that appeared only a few years ago. Up to now, it was very often overlooked. The current situation is helping digital health to show its full potential. For example, Digital health can be used as a triage system, finding out what kind of illness a patient has with chatbots and telemedicine solutions. Afterward, the patients can be referred to real-life doctors - to the right one.

    A solution Symptoma has developed. In this episode, I am talking with the CEO of Symptoma, Jama Nateqi, about the real potential of digital health.

    Another novel technology appeared recently - blockchain. Astrid Woollard, Partner at Scytale Ventures, is investing in companies that develop blockchain-based solutions. She has joined us to chat about the leverage blockchain can provide for digital health and the entire healthcare system.

    Link to the Video of the Recording:
    YouTube

    Speaker:
    Astrid Woollard (https://www.linkedin.com/in/astridwoollard/)
    Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
    Jama Nateqi (https://www.linkedin.com/in/jama-nateqi/)

    Companies:
    CS Life Science Invest (https://www.cslifescienceinvest.com/)
    Scytale Ventures (https://scytale.ventures/)
    Symptoma (https://www.symptoma.com/)

    Do you enjoy the podcast?
    Become a member of the LSG2G Network and join the recording. You will get an individual "member only" invitation and will have a chance to talk with the speakers in the Q&A. The best questions will be featured in the podcast. Do you like this idea? Join today: Newsletter

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    51 min
  • #10: Shining a light on TechTransfer - A chat with Saara Inkinen from Nordic Catalyst

    Viral threats to humankind like the Coronavirus need scientists from all over the world collaborating to solve the problem. People like Saara Inkinen support scientists and universities to transfer their inventions to companies who turn science into products.

    These products help patients to overcome illnesses and stay healthy. In this episode you will get some information how Saara helps in that area.

    More information:

    Nordic Catalyst (https://www.nordiccatalyst.com/)
    LSG2G (https://www.lifescienceget2gether.com/)


    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    18 min
  • #9: Alexander Belcredi (PhagoMed) – Can Viruses Beat Superbugs?

    When antibiotics fail, could a virus help?

    Phages are viruses that infect and kill bacteria. Alexander Belcredi co-founded PhagoMed to turn them into medicines for patients with difficult bacterial infections.

    His interest began with a surgeon’s frustration. His father-in-law had used phages experimentally when antibiotics failed. Why weren’t there approved medicines he could prescribe more regularly?

    That question brought together three founders with different skills: a surgeon, a molecular biologist, and a business professional.

    In this episode of Beginner’s Mind, Alexander, then PhagoMed’s Co-CEO, joins Christian Soschner to explain how phages work, why antibiotic resistance creates an urgent need for new treatments, and what researchers still needed to prove.

    We also explore the business behind the science: financing drug development, combining public grants with private investment, choosing investors, and planning milestones that make the next funding round possible.

    Recorded in 2020. References to clinical trials, funding plans, and the company’s development stage reflect that period.

    WHAT YOU WILL LEARN

    • Why some viruses could help fight antibiotic-resistant bacteria
    • What makes phages different from conventional antibiotics
    • Why promising science still needs rigorous clinical evidence
    • How scientific, medical, and business expertise fit together in a founding team
    • How public funding can support private investment in European biotech
    • How to prepare for fundraising—and set realistic expectations about the process

    CHAPTERS

    (00:00) Opening
    (02:26) Meet Alexander Belcredi
    (03:30) The question that led to PhagoMed
    (06:45) Phages: an alternative to antibiotics
    (08:10) Why not all viruses are harmful
    (09:20) Why we need more treatments for bacterial infections
    (10:50) The emerging phage-therapy industry
    (12:30) Phage clinical trials: the picture in April 2020
    (14:35) Where phage treatments were available in 2020
    (16:30) How much capital does drug development require?
    (18:15) Funding an early-stage biotech in Europe
    (20:00) Preparing for fundraising
    (23:30) When should founders start raising money?
    (25:00) Fundraising expectations, rejection, and success rates
    (30:45) PhagoMed’s biggest fundraising challenge
    (32:30) Is there an ideal time to raise capital?
    (35:20) From opening a funding round to closing it
    (36:55) Preparing a Series A round in 2020
    (37:55) Planning milestones for a Series A
    (39:05) Combining European public funds with private investment
    (42:25) Advice Alexander would give his younger self

    WATCH THE CONVERSATION

    https://youtu.be/YHTR8yMoC3w

    EPISODE NOTES

    Read the summary and key takeaways on Podcast Notes:
    https://podcastnotes.org/beginners-mind/episode-9-alternatives-to-antibiotics-a-talk-with-alexander-belcredi-ceo-and-founder-of-phagomed-beginners-mind-with-christian-soschner/

    KEEP EXPLORING

    Follow Beginner’s Mind for conversations with the founders and investors turning breakthrough science into companies.

    Subscribe to the newsletter:
    https://lsg2g.substack.com/subscribe

    Your Next Move: https://www.cslifescienceinvest.com/


    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    39 min
  • #8: European Tech Hubs - a Panel Discussion at the Resi Conference

    This week I had the honor to moderate a panel discussion at the RESI conference (https://www.resiconference.com/). It is one of the most important meetings for early-stage investment in the United States. Life Science Nation is the organizer of the event series. Last year in March the RESI conference visited Europe for the first time. The city of choice was Vienna. I invited Dennis Ford and Greg Mannix to visit the Life Science Get2gether #8. 

    At the RESI conference in Vienna, I had the opportunity to speak at the Panel - how business angels and family offices view seed and Series A rounds? At the time of the Bio US, I again supported the RESI conference as a speaker. This time we were talking about European Tech Hubs. 

    This year the conference is back in Europe. Well, due to the actual situation with the Corona Virus the conference turned digital. Last Monday we recorded the European tech Hub panel. At the panel, I had the opportunity to speak with 3 speakers about their model and the situation for Investors in Europe.

    Institutional life science investors such as VCs or family offices are looking for assets that are de-risked and have data packages that indicate potential efficacy and safety – however, reaching that point takes substantial funding that’s not easy to find. Life science entrepreneurs need novel funding and development solutions that help them overcome this steep funding challenge at the very earliest stage of company formation, typically in years 0-3 of a company’s life. In this RESI panel, the audience can learn about new initiatives that are creating opportunities for life science startups to thrive in Europe.

    The speaker:

    Jeroen Blokhuis, PhD is the Chief Business Officer of the Pivot Park in the Netherlands. Pivot Park is an 8-year young Dutch Science Park, formally the R&D campus of Organon, that in the past was acquired by Shering-Plough, then acquired by MSD, and then given back to municipality in 2012. The Pivot Park now houses 60+ biotech startups and scale-ups, including Acerta-Pharma.

    Dr. Irene Fialka is CEO of INiTS, Vienna’s University Business Incubator (UBI) serving all academic institutions in Vienna. She has a background in genetics and has worked with R&D-based deep-tech startups since 2004. INiTS has been ranked amongst the TOP20 UBIs worldwide since 2013 by UBI Global (ubi-global.com). INiTS’ startups outperform creating jobs, raising funds and finding strategic partners. Some examples are Apeptico, Lexogen, Marinomed (INiTS’ 1st IPO), MedicusAI, mySugr, S-TARget etc. She is co-founder of investorinnen.com (female investing) and Women in Health IT and since 2018 managing partner of healthhubvienna.com, an international acceleration program to drive innovation in healthcare. 

    Olivier Nosjean is the Research Scientific Director at Servier. A biochemist by training, he has been a drug discovery researcher and manager for 20 years. He established and has been a contributor to a range of public/private partnerships throughout the world, focused on therapeutic innovation and on scientific and technology expertise. Olivier is currently leading the technology innovation strategy and the Program for PhD students and Post-docs at Servier. He is an active contributor to Servier initiatives related to open innovation, entrepreneurship and strategic partnerships. One of his most exciting actions today are dedicated to preparing the opening of a drug discovery incubator along with the new research site of Servier currently under construction.

    More information: 

    linktr.ee/soschner
    lifescienceget2gether.com

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    52 min
  • EP 7: Michael Lukesch | What Building a Biotech Really Costs

    Many first biotech raises fall into the same gap. The round is too large for business angels and too small for biotech venture capital (VC) funds.

    Michael Lukesch hit that gap in 2019. He was still enrolled in a PhD program. He had a university patent, a co-founder, and seed money from a four-month accelerator in Ireland. He closed the first financing round for Valanx Biotech anyway.

    Michael Lukesch is the CEO of Valanx Biotech in Lower Austria. Valanx works on protein conjugation. This is the step where drug developers attach a polymer or a small molecule to an antibody or another protein to improve its effect as a therapy. Today’s methods produce a random mix of products. Valanx controls how many attachments there are and where they go.

    He recorded this conversation in early 2020. He explains how a PhD that stopped going to plan led him into a company, what the RebelBio accelerator taught him about pitching, which three filters ruled out most investors, why he keeps a newsletter list of the investors who said no, and what he would tell his younger self.

    WHAT YOU WILL LEARN

    • How a PhD student turns a university patent into a company
    • Why a seed round can be too large for angels and too small for biotech funds
    • How to explain a niche technology to an investor with three minutes of attention
    • What a biotech company costs once lab equipment and salaries arrive
    • Why the choice between own products and technology provider decides the next round

    BEST QUOTES

    • (00:05:08) “97% of PhD students won’t get a full-time position in academia.”
    • (00:05:55) “A lot of people are not even aware that you can do your own company.”
    • (00:11:23) “For business angels we were raising too much. For proper biotech investors, I was just too small.”
    • (00:19:34) “100,000 euros sounds like a lot of money. Until you have to finance lab equipment and pay salaries.”
    • (00:20:02) “We could have just moved a bit faster.”

    TIMESTAMPS

    THE PATH IN

    • (00:00:07) Intro
    • (00:02:44) From environmental science to biochemistry
    • (00:04:50) When the PhD plan stopped working
    • (00:06:26) From a university patent to a company
    • (00:07:20) Funding the start at the RebelBio accelerator in Ireland

    THE TECHNOLOGY

    • (00:08:42) The protein conjugation problem
    • (00:09:45) Proof of concept and the first round

    RAISING MONEY

    • (00:10:36) Focus, geography and ticket size
    • (00:12:36) Explaining a niche technology fast
    • (00:14:45) Investor speed dating at BIOVARIA
    • (00:15:39) A newsletter for the investors who said no

    WHAT COMES NEXT

    • (00:16:29) New lab, first product, pharma partners
    • (00:18:01) Own products or technology provider
    • (00:18:54) Three lessons for his younger self
    • (00:20:47) Closing

    Michael Lukesch on LinkedIn: https://www.linkedin.com/in/michaellukesch/
    Valanx Biotech: https://valanx.bio

    Follow Beginner’s Mind for long-form conversations on leadership, capital, technology, and the people building what comes next.

    Ranked in the global top 10% of all podcasts, named #1 Deep Tech Podcast in 2025, and #8 Deep Tech Podcast in 2026

     

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    22 min
  • #6: No sales? This might be the reason

    Did you ever wonder: Whatever effort you spent with potential clients. The sales figure doesn’t go up. Instead, it is moving down. The more time you spent with potential clients, the less you sell. Well, trying to convince the unconvinceable might be the reason.
    In this episode, Christian speaks about the importance of selecting the right approach towards potential customers.

    Read the script to this episode at medium (https://medium.com/@christian.soschner/no-sales-that-might-be-the-reason-fe66eae649fa?source=friends_link&sk=21ac770d4dc263b21424493cf5fb9580)

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    7 min
  • #5: Making Money with Coffee

    How to turn a daily habit into an investment. Some thoughts on savings, investment and making money.

    More information: 

    Linktr.ee/soschner  

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    4 min
  • #4 The story behind LSG2G

    In 2017 I created the Life Science Network LSG2G. This is a brief overview of the history and the next event.

    More information at lifescienceget2gether.com

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    5 min
  • #3: A business needs paying customers

    There is this thing that some people demand free work. My take on it. Script: https://medium.com/@christian.soschner/a-business-needs-paying-customers-7cb8f1c6e4a3?source=friends_link&sk=299243e18054aa66acb69b02ec31b56d

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    4 min
  • #2: Lottery Winner?

    Thoughts about money managing skills. Script: https://medium.com/@christian.soschner/lottery-winner-3ced34ee9d48?source=friends_link&sk=230f2f2a4a0193d4dd435cfc5d278872

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    13 min